Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | RHOC | P08134 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904222 | 1.00 | CNR2 (0.43) | CNR2TDP1HCRTR1RHOCRHOA | |
| SCHEMBL15904014 | 0.90 | MMP2 (0.46) | CNR2TDP1HCRTR1RHOCRHOA | |
| SCHEMBL17313720 | 0.90 | MMP2 (0.46) | CNR2TDP1HCRTR1RHOCRHOA | |
| SCHEMBL15904691 | 0.86 | TDP1 (0.54) | TDP1HCRTR1L3MBTL1 | |
| SCHEMBL15904212 | 0.83 | CA2 (0.51) | TDP1L3MBTL1 | |
| SCHEMBL15904210 | 0.83 | CA2 (0.51) | TDP1L3MBTL1 | |
| SCHEMBL15903711 | 0.74 | TDP1 (0.52) | TDP1L3MBTL1HPGDGAA | |
| SCHEMBL15904535 | 0.73 | TDP1 (0.51) | TDP1L3MBTL1HPGDGAA | |
| SCHEMBL15904694 | 0.73 | TDP1 (0.51) | TDP1L3MBTL1HPGDGAA | |
| SCHEMBL15904060 | 0.73 | TDP1 (0.51) | TDP1L3MBTL1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CNR2 4825/4885TDP1 1723/4885HCRTR1 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.